|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 48/00 | |
| A61K 31/7105 | |||
| C12N 15/113 | |||
| A61P 35/00 | |||
| A61K 38/17 |
| (11) | Patento numeris | 2470217 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10812443.9 |
| Europos patento paraiškos padavimo data | 2010-02-19 | |
| (97) | Europos patento paraiškos paskelbimo data | 2012-07-04 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-10-07 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2010/024740 |
| Data | 2010-02-19 |
| (87) | Numeris | WO 2011/025556 |
| Data | 2011-03-03 |
| (30) | Numeris | Data | Šalis |
| 708294 | 2010-02-18 | US | |
| 546292 | 2009-08-24 | US |
| (72) |
DONALD, Carlton, D., US
|
| (73) |
Phigenix, Inc.,
191 Peachtree Street, Suite 3300, Atlanta, GA 30303,
US
|
| (54) | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER |
| TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER |